NeuroVision Imaging has acquired Durin Life Sciences, combining blood-based biomarker tests with retinal imaging and telehealth to advance early detection of Alzheimer’s and Parkinson’s diseases.
Researchers at UCLA have developed a low-cost blood test, MethylScan, that detects multiple cancers and liver diseases by analyzing DNA methylation patterns in cell-free DNA.
The FDA has granted Breakthrough Device designation to PreludeDx’s AidaBREAST assay, which uses multi-omic data and AI to assess recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
ClearNote Health will present data at DDW 2026 showing its Avantect Pancreatic Cancer Test achieved 82.6% sensitivity and 97.5% specificity in patients at elevated risk.
A Boston University study found TB DNA in 12% to 16% of respiratory samples from hospitalized patients in a low-incidence area using an ultrasensitive assay, suggesting underdiagnosis of tuberculosis in the US.
Utepreva LLC has received FDA clearance for its single-use endometrial sampler, which employs three sampling mechanisms to improve tissue yield for cytologic and molecular analysis in early endometrial cancer detection.
The Elecsys NfL test measures a protein associated with nerve cell injury to monitor disease activity in patients with relapsing remitting multiple sclerosis.
The ACC, AHA, and nine other associations have issued an updated dyslipidemia guideline, recommending earlier intervention and expanded use of lipoprotein(a) and apolipoprotein B testing to improve cardiovascular risk assessment.
Circular Genomics and Vitazi.ai have formed a partnership to combine AI-driven retinal imaging and blood-based RNA biomarkers for early Alzheimer’s disease detection, aiming to address gaps in early-stage patient identification.
HistoIndex has partnered with Houston Research Institute and Knowledge Research Center to expand access to AI-driven digital pathology for liver disease diagnostics in Texas and California.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A multicenter, vignette-based study found that adding a rapid sepsis test result to standard clinical data changed or reinforced diagnostic decisions in 86% of cases.